Lorlatinib plus Sacituzumab Tirumotecan with Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: cd8419f6db1ffa157f1a5e5eb1c575ad297e786a
First added on: Oct 10, 2026